Clinical Trials · NCT06221696

Preventing Weight Regain Post-Semaglutide Treatment With Active Fiber Supplement (Soloways)

Name: Preventing Weight Regain Post-Semaglutide Treatment With Active Fiber Supplement (Soloways)
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedN/ASemaglutide

Phase: N/A
Recruitment status: Completed
Sponsor: S.LAB (SOLOWAYS)
Enrollment: 160
Start date: Jun 2023
Locations: 1 site, Russia
Primary endpoint: Percentage of weight regain from baseline

View Semaglutide compound reference